SanionaToggle sidemenu
  • About Saniona
    • Corporate Governance
      • Articles of association
      • Shareholder meetings
      • Nomination Committee
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Executive Management
      • Auditors
      • Corporate Governance Reports
      • Policies
      • Remuneration
    • Our Vision
    • Strategy and Business Model
  • Proprietary Pipeline
    • Tesomet
    • SAN711
    • SAN903
  • Partnered Pipeline
    • Tesofensine
    • CAD-1883
    • Boehringer Ingelheim
  • Investors
    • Share information
    • Frequently asked questions
    • Unit rights Issue 2020
    • Warrants of series TO 1
    • Warrants of series TO 2
    • Ownership structure
    • Analyst coverage
    • Financial calendar
    • Financial reports
    • Company presentations
    • Interviews & Webcasts
    • Propectus August 2020
  • News
  • Careers
    • Denmark
    • United States
  • English Swedish

    OMX: SANION 18.02 -0.99 %

  • About Saniona
    • Corporate Governance
      • Articles of Association of Saniona AB (publ) Reg. no. 556962-5345
      • Shareholder meetings
      • Nomination Committee
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Executive Management
      • Auditors
      • Corporate Governance Reports
      • Policies
      • Remuneration
    • Our Vision
    • Strategy and Business Model
  • Proprietary Pipeline
    • Tesomet for treatment of Prader-Willi Syndrome and Hypothalamic Obesity
    • SAN711 for the treatment of rare neuropathic disorders
    • SAN903 for rare inflammatory and fibrotic disorders
  • Partnered Pipeline
    • Tesofensine for treatment of obesity
    • CAD-1883 for treatment of tremor and spinocerebellar ataxia
    • Boehringer Ingelheim collaboration for treatment of schizophrenia
  • Investors
    • Share information
    • Frequently asked questions
    • Unit rights Issue 2020
      • Prospectus
    • Warrants of series TO 1
    • Warrants of series TO 2
    • Ownership structure
    • Analyst coverage
      • 2019 Reports
      • 2018 Reports
      • 2017 Reports
      • 2016 Reports
      • 2015 Reports
      • 2014 Reports
    • Financial calendar
    • Financial reports
    • Company presentations
    • Interviews & Webcasts
    • Propectus August 2020
      • Propectus
  • News
  • Careers
    • Denmark
    • United States
  • English Swedish

    OMX: SANION 18.02 -0.99 %

  • Home
  • Privacy policy

Saniona

Smedeland 26B 
2600 Glostrup 
Denmark

Telephone
+45 70 705 225
Email
saniona@saniona.com
Sign up to our press releases
Home Investors Analyst coverage 2016 Reports

2016 Reports

Date Analyst Language Analyst Report
2016/11/08 Kapital Partner DK 20161108 Kapital Partner
2016/10/03 Redeye UK 20161003 Redeye
2016/10/03 Redeye SWE 20161003 Redeye
2016/04/08 Kapital Partner DK 20160408 Kapital Partner
2016/03/11 Redeye SWE 20160311 Redeye

Investors

  • Share information
  • Frequently asked questions
  • Unit rights Issue 2020
  • Warrants of series TO 1
  • Warrants of series TO 2
  • Ownership structure
  • Analyst coverage
  • Financial calendar
  • Financial reports
  • Company presentations
  • Interviews & Webcasts
  • Propectus August 2020
  

Sign up to our press releases

Saniona
  • Home
  • Privacy policy

All Rights Reserved · Saniona · 2021

Scroll to top

Smedeland 26B 
2600 Glostrup 
Denmark

Telephone
+45 70 705 225
Email
saniona@saniona.com

500 Totten Pond Road (Suite 620)
Waltham, MA 02451
USA

Telephone
+1-781-839-9100